Literature DB >> 26590187

Novel oral anticoagulants and HIV: dabigatran use with antiretrovirals.

Jacinta Perram1, Joanne Joseph1, Cameron Holloway1.   

Abstract

Compatibility of novel oral anticoagulants in patients with HIV taking combined antiretroviral therapy has not been established, with no published reports of successful concurrent use. We present a case where chronic anticoagulation was indicated in a patient with treated HIV and non-valvular atrial fibrillation who refused warfarin therapy. The patient tolerated the combination, with dabigatran blood levels within the expected range at a standard dosing regimen, without evidence of bleeding or other adverse outcomes. While further research is needed to establish the role of novel oral anticoagulants in patients taking antiretrovirals, this case suggests that dabigatran may be a viable option for selected patients. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26590187      PMCID: PMC4680264          DOI: 10.1136/bcr-2015-211651

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia.

Authors:  Christopher X Wong; Anthony G Brooks; Darryl P Leong; Kurt C Roberts-Thomson; Prashanthan Sanders
Journal:  Arch Intern Med       Date:  2012-05-14

Review 2.  Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications.

Authors:  Gregory Egan; Christine A Hughes; Margaret L Ackman
Journal:  Ann Pharmacother       Date:  2014-03-10       Impact factor: 3.154

Review 3.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

4.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Authors:  Paul A Reilly; Thorsten Lehr; Sebastian Haertter; Stuart J Connolly; Salim Yusuf; John W Eikelboom; Michael D Ezekowitz; Gerhard Nehmiz; Susan Wang; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2013-09-27       Impact factor: 24.094

Review 5.  New oral anticoagulants for atrial fibrillation: a review of clinical trials.

Authors:  Kate M O'Dell; Daniel Igawa; Jerline Hsin
Journal:  Clin Ther       Date:  2012-03-13       Impact factor: 3.393

6.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

7.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Authors:  A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

8.  Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity.

Authors:  Jonathan C Hsu; Yongmei Li; Gregory M Marcus; Priscilla Y Hsue; Rebecca Scherzer; Carl Grunfeld; Michael G Shlipak
Journal:  J Am Coll Cardiol       Date:  2013-04-03       Impact factor: 24.094

9.  Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system.

Authors:  Felicia C Chow; Susan Regan; Steven Feske; James B Meigs; Steven K Grinspoon; Virginia A Triant
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-01       Impact factor: 3.731

Review 10.  Warfarin-antiretroviral interactions.

Authors:  Michelle D Liedtke; R Chris Rathbun
Journal:  Ann Pharmacother       Date:  2009-02-05       Impact factor: 3.154

  10 in total
  9 in total

1.  Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers.

Authors:  Lori A Gordon; Parag Kumar; Kristina M Brooks; Anela Kellogg; Maryellen McManus; Raul M Alfaro; Khanh Nghiem; Jomy M George; Jay Lozier; Scott R Penzak; Colleen Hadigan
Journal:  Circulation       Date:  2016-12-06       Impact factor: 29.690

Review 2.  Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.

Authors:  Alice Tseng; Christine A Hughes; Janet Wu; Jason Seet; Elizabeth J Phillips
Journal:  Ann Pharmacother       Date:  2017-06-19       Impact factor: 3.154

3.  Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.

Authors:  Parag Kumar; Lori A Gordon; Kristina M Brooks; Jomy M George; Anela Kellogg; Maryellen McManus; Raul M Alfaro; Khanh Nghiem; Jay Lozier; Colleen Hadigan; Scott R Penzak
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.

Authors:  Payal P Kakadiya; Patricia Pecora Fulco; Robert T Higginson
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

Review 5.  Prevention of stroke in people living with HIV.

Authors:  Ivy Nguyen; Anthony S Kim; Felicia C Chow
Journal:  Prog Cardiovasc Dis       Date:  2020-01-31       Impact factor: 8.194

6.  Prescribing of two potentially interacting cardiovascular medications in atrial fibrillation patients on direct oral anticoagulants.

Authors:  Mohammed Shurrab; Maria Koh; Cynthia A Jackevicius; Feng Qiu; Michael Conlon; Joseph Caswell; Karen Tu; Peter C Austin; Dennis T Ko
Journal:  Int J Cardiol Heart Vasc       Date:  2021-04-29

7.  Venous thromboembolic disease in adults admitted to hospital in a setting with a high burden of HIV and TB.

Authors:  P Moodley; N A Martinson; W Joyimbana; K N Otwombe; P Abraham; K Motlhaoleng; V A Naidoo; E Variava
Journal:  Afr J Thorac Crit Care Med       Date:  2021-10-04

8.  Embolizing Massive Right Atrial Thrombus in a HIV-Infected Patient.

Authors:  Piruthiviraj Natarajan; Fowrooz Joolhar; Sudhagar Thangarasu; Ayham Aboeed; Theingi Tiffany Win; Everardo Cobos
Journal:  J Investig Med High Impact Case Rep       Date:  2018-09-28

Review 9.  Stroke and Systemic Thromboembolism Prevention in People Living With Human Immunodeficiency Virus With Atrial Fibrillation: A Review of Its Implications for Clinical Practice.

Authors:  Pilar Vizcarra; Silvia Guillemi; Oghenowede Eyawo; Robert S Hogg; Julio S Montaner; Matthew Bennett
Journal:  CJC Open       Date:  2019-07-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.